Skip to main content

Table 2 Probability of occurrence of changes in TVR combination treatment arms, based on a TVR-naïve dataset

From: Compensatory substitutions in the HCV NS3/4A protease cleavage sites are not observed in patients treated unsuccessfully with telaprevir combination treatment

   

TVR-naïve dataset

TVR-resistant dataset

 

Position

Site

AA

x†

X‡

f(%)

n†

N‡

F(%)

Prob (F|f)

NS3 625

P7

T

0

3488

0.00

1

116

0.86

0.0322*

NS4A 9

P9’

I

4

3488

0.11

1

116

0.86

0.1165

NS4A 45

P10

H

0

3488

0.00

1

116

0.86

0.0322*

NS4B 2

P2’

L

5

3469

0.14

1

116

0.86

0.1415

NS4B 2

P2’

A

22

3469

0.63

1

116

0.86

0.3525

NS4B 4

P4’

F

5

3483

0.14

1

116

0.86

0.1410

NS4B 254

P8

G

2

776

0.26

1

43

2.33

0.0992

NS5A 2

P2’

S

2

772

0.26

1

43

2.33

0.0997

NS5A 440

P9

G

8

765

1.05

1

43

2.33

0.2868

NS5A 441

P8

P

0

761

0.00

1

43

2.33

0.0534*

NS5A 441

P8

T

3

761

0.39

2

43

4.65

0.0121*

NS5B 7

P7’

S

0

777

0.00

1

43

2.33

0.0524*

  1. †  n,x: denote the number of times each residue was observed in each dataset; ‡  N,X: indicate the sample size for each dataset.
  2. * prob- values associated with any residues which are not observed in the TVR-naïve dataset (i.e., x = 0) are marked with an asterisk. The neutrally expected frequency of these amino acids at these positions can only be defined as < 1/X; therefore calculations for each of these positions assume 1 occurrence of the residue in the TVR-naïve dataset. Probability values for these residues should therefore be interpreted as upper bounds.
Back to article page

Virology Journal

ISSN: 1743-422X